A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jan 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging called 68Ga-PSMA-11 PET/CT scans to see how well it can assess tumors in people with high-grade glioma or brain metastases. The goal is to understand how active these tumors are, which can help doctors make better decisions about treatment. The trial is currently looking for adult participants who are at least 18 years old and have a confirmed diagnosis of high-grade glioma or brain metastases, with tumors that are large enough to be biopsied (at least 1 cm in size).

To participate, individuals need to be able to give informed consent, meaning they understand the study and agree to take part. They also need to be scheduled for a biopsy or surgery to remove the brain lesion. However, some people may not be eligible, such as those who can't undergo a PET scan due to certain medical conditions or those who are pregnant or nursing. Participants in the trial can expect to undergo the PET scan, which is a non-invasive procedure that helps doctors visualize the activity of the tumor. This study is important because it could improve how brain tumors are assessed and lead to better treatment options for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
• • Adults ≥ 18 years old
• • Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
• • Lesion size ≥ 1 cm (for the lesion to be biopsied)
• • ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
• • Planned to undergo biopsy/resection of brain lesion
• Exclusion Criteria:
• • Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
• • Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test \<1 week before study.
• • Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• • Patients with severe allergy to both iodinated and gadolinium contrast.